Assetmark Inc. increased its stake in Gilead Sciences, Inc. by 22.5% in the third quarter, purchasing an additional 28,701 shares, bringing its total holdings to 156,118 shares valued at $17,329,000. Other institutional investors have also made significant changes to their positions in the biopharmaceutical company. Analysts have maintained a “Moderate Buy” consensus rating and a target price of $152.50 for GILD, following positive Q4 earnings, raised FY26 guidance, and pipeline catalysts.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Assetmark Inc. Acquires 28,701 Shares of Gilead Sciences, Inc. $GILD
Assetmark Inc. increased its stake in Gilead Sciences, Inc. by 22.5% in the third quarter, purchasing an additional 28,701 shares, bringing its total holdings to 156,118 shares valued at $17,329,000. Other institutional investors have also made significant changes to their positions in the biopharmaceutical company. Analysts have maintained a “Moderate Buy” consensus rating and a target price of $152.50 for GILD, following positive Q4 earnings, raised FY26 guidance, and pipeline catalysts.